CCCecile N. Chougnet

Cecile N. Chougnet

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Cecile N. Chougnet has a total of 72 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Rapid and long-lasting response to selpercatinib of paraneoplastic Cushing’s syndrome in medullary thyroid carcinoma

    by Marine Sitbon, Porhuoy Chou, Seydou Bengaly, Brigitte Poirot, Marie Laloi-Michelin, Laure Deville, Atanas Pachev, Ahouefa Kowo-Bille, Clement Dumont, Cécile N Chougnet

    The endocrine secretions of carcinomas can be life-threatening. Medullary thyroid carcinoma (MTC) is a rare cancer that is often associated with cortisol secretion, leading to paraneoplastic Cushing’s syndrome. Mutations of the proto-oncogene RET are driver molecular events in 70% of MTC cases. Here, we report a case of a woman, born in 1956, who was diagnosed with sporadic MTC in 2005, with subsequent relapses treated with focal treatments. In April 2019, she presented with severe and rapidly progressive paraneoplastic Cushing’s syndrome associated with lymph node, lung, liver and bone metastases. A supraclavicular lymph node biopsy revealed a somatic p.M918T (c.2753T>C) mutation in exon 16 of the RET proto-oncogene. The patient began treatment with selpercatinib in September 2019. Clinical efficacy was immediate. Chronic diarrhea disappeared within a few days. Clinical hypercorticism quickly disappeared, with quick improvements in muscle and skin conditions and fatigue. Two months after treatment initiation, urinary free cortisol normalized to 42 µg/24 h. Levels of the tumor markers carcinoembryonic antigen (CEA) and calcitonin also greatly decreased from baseline. After 34 months of treatment, selpercatinib elicits sustained clinical, biological and morphological responses. In summary, this case report illustrates the rapid and long-lasting antisecretory effect of selpercatinib associated with tumor control. As Cushing’s syndrome associated with medullary thyroid cancer is associated with poor prognosis, this case report is very encouraging. In addition, this suggests the potential benefit of molecular testing in all cases of medullary thyroid cancer.


  • Open Access

    Intermittent versus continuous administration of pazopanib in progressive radioiodine refractory thyroid carcinoma: Final results of the randomised, multicenter, open-label phase II trial PAZOTHYR

    by Christelle de la Fouchardière, Yann Godbert, Cécile Dalban, Frédéric Illouz, Johanna Wassermann, Christine Do Cao, Stéphane Bardet, Slimane Zerdoud, Cécile N. Chougnet, Mohamed Zalzali, et al.


  • Imaging-guided precision medicine in non-resectable gastro-entero-pancreatic neuroendocrine tumors: A step-by-step approach

    by Laura Rozenblum, Fatima-Zohra Mokrane, Randy Yeh, Mathieu Sinigaglia, Florent L. Besson, Romain-David Seban, Charline Zadro, Lawrence Dierickx, Cecile N Chougnet, Ephraim Partouche, et al.


  • Open Access

    Successful Treatment of Differentiated Thyroid Carcinoma with Transaxillary Robotic Surgery and Radioiodine: The First European Experience

    by Marie Alix Balay, Patrick Aidan, Marie Helene Schlageter, Odette Georges, Taly Meas, Maroun Bechara, Marie Elisabeth Toubert, Isabelle Faugeron, Herve Monpeyssen, Cécile N. Chougnet

    Objectives: Transaxillary robotic thyroidectomy surgery (TARS) has been reported to be a safe approach in patients with differentiated thyroid carcinoma, and oncological responses are promising. Study Design: This study aimed to evaluate the oncological outcomes of TARS followed by radioiodine (RAI) therapy in patients with differentiated thyroid carcinoma. Between 2011 and 2016, patients treated for differentiated thyroid carcinoma by TARS in a single institution, followed by RAI, were retrospectively included. The oncological response was performed according to the 2015 American Thyroid Association (ATA) guidelines 6–12 months later and at the last available visit. Results: A total of 42 patients (30 females) were included, with a median tumor size of 20 mm (12 cases of N1a and 5 cases of N1b on initial pathology report). According to ATA classification of recurrence risk after surgery, 17 and 25 patients were classified as low and intermediate risk, respectively. After RAI, all patients had a normal posttherapeutic whole body scan (except 1 patient, who had pathological lymph node uptake), but no unusual uptake was seen. At the 6- to 12-month evaluation (n = 37), 24 patients had excellent response, 8 had indeterminate response, and 5 had incomplete response (2 biological and 3 structural); no distant metastasis was found. At the last evaluation (median follow-up 15.9 months), 35 patients had no evidence of disease and 1 patient had a structural incomplete response. In total, a second open surgery was necessary for 3 patients to treat persistent lymph nodes (all intermediate risk). Conclusion: In this study, TARS followed by RAI therapy seems to be curative, even for patients with lymph node metastases, after good preoperative staging. More studies are required to confirm the findings.


  • Quel bilan d’imagerie fonctionnelle et biologique faire au diagnostic et dans le suivi d’une tumeur neuroendocrine intestinale ?

    by L. Rozenblum, L. Vercellino, C. N. Chougnet

    Les techniques d’imagerie fonctionnelle sont recommandées au diagnostic et dans le suivi des tumeurs neuroendocrines (TNE) intestinales. Le choix du traceur est fonction du site primitif et du grade de la TNE. Pour les TNE digestives bien différenciées, la tomographie par émission de positons (TEP) à la 18F-DOPA ainsi que la TEP au 68Ga-DOTATOC ou encore la scintigraphie des récepteurs de la somatostatine (SRS) peuvent aider à la prise en charge du patient, en permettant la détection du primitif et des métastases, l’évaluation de l’extension et de la réponse au traitement. Pour les tumeurs plus agressives, notamment les TNE du côlon et du rectum, la TEP au 18F-FDG est plus pertinente. La SRS et la TEP DOTATOC permettent également de sélectionner les patients éligibles à un traitement par analogue de la somatostatine radiomarqué. Le marqueur biologique de la TNE est la chromogranine A, mais de nombreuses interférences sont possibles (faible spécificité). Le dosage des 5-HIAA urinaires dans la TNE du grêle permet de diagnostiquer un syndrome carcinoïde.


  • Not All Patients with a Pancreatic Neuroendocrine Tumour Will Benefit from All Approved or Recommended Therapeutic Options: A Real-Life Retrospective Study

    by Amandine Berdelou, Valérie Boige, Julia Arfi-Rouche, David Malka, Stéphane Ederhy, Hassan Izzedine, Sophie Leboulleux, Cécile N. Chougnet, Pascal Burtin, Thierry De Baere, et al.

    Background: At least nine therapeutic options are recommended or approved for pancreatic neuroendocrine tumour (pNET). The primary endpoint of this study was to determine the number of therapeutic lines given before death. Secondary endpoints were to determine toxic events as a function of number of therapeutic lines and of time. Methods: Patients with pNET treated between 1998 and 2010 at our centre were characterised. All therapeutic lines were recorded as well as tumour- or toxic-related deaths. Persistent treatment-related toxicity (PTRT) was defined as: chronic kidney disease, anaemia, thrombocytopenia, neutropenia, severe liver failure, cardiac failure and recurrent sepsis, precluding at least one other therapeutic option or second cancers. Results: Ninety-two patients were analysed. The median follow-up was 7 years. The 1-, 2- and 5-year overall survival rates were 90, 81 and 51%, respectively. After 3 and 5 therapeutic lines, 23 and 50% of patients had died, respectively. After 3 and 5 lines, the frequency of toxic events was 8 and 24%, respectively. Overall, 17 toxic events were observed including 6 treatment-related deaths and 11 PTRT. After 1, 2 and 5 years of treatment, the frequency of toxic events was 6, 9 and 16%, respectively. Conclusion: Tumour- and toxic-related deaths as well as PTRT may preclude access to all therapeutic options in patients with pNET. Optimised risk benefit sequence should be investigated.


  • Vandétanib, modalités pratiques d’utilisation dans le traitement des patients atteints de cancer médullaire de la thyroïde

    by Cecile N. Chougnet, Martin Schlumberger, Sophie Leboulleux, Eric Baudin

    Medullary thyroid cancer (MTC) is a rare cancer. Vandetanib, a RET tyrosine-kinase inhibitor, significantly increased progression free survival and is the first treatment approved in France for unresectable, locally advanced or metastatic MTC that is symptomatic or progressive. Most frequents adverse events are diarrhea, folliculitis and asthenia. The prolongation of the QT interval on electrocardiogram is frequent but in the most of cases not clinically relevant. A good selection of the patients who could benefit from this treatment and management of side effect are important for the risk-benefit assessment.


  • Open Access

    Kinase inhibitors for advanced medullary thyroid carcinoma

    by Martin Schlumberger, Marie-Hélène Massicotte, Camila L. Nascimento, Cécile Chougnet, Eric Baudin, Sophie Leboulleux

    The recent availability of molecular targeted therapies leads to a reconsideration of the treatment strategy for patients with distant metastases from medullary thyroid carcinoma. In patients with progressive disease, treatment with kinase inhibitors should be offered.